干扰素β-1a联合瑞德西韦治疗住院COVID-19患者的疗效:双盲随机安慰剂对照3期试验
这项在5国63家医院开展的双盲随机安慰剂对照3期试验纳入969例住院COVID-19成人患者,比较干扰素β-1a联合瑞德西韦与单用瑞德西韦的疗效。
要点
- 干扰素β-1a联合瑞德西韦未缩短住院COVID-19患者的恢复时间。
- 联合治疗组28天死亡率与单药组无显著差异。
- 基线需高流量氧疗者接受联合治疗后不良事件和严重不良事件更多。
核心结论
- 在住院COVID-19肺炎患者中,干扰素β-1a联合瑞德西韦不优于单用瑞德西韦。
- 基线需高流量氧疗的患者接受干扰素β-1a联合治疗后结局更差。
研究设计与样本
- 双盲、随机、安慰剂对照3期试验,在5国63家医院开展。
- 纳入969例住院成人COVID-19患者,随机1:1接受干扰素β-1a联合瑞德西韦(n=487)或安慰剂联合瑞德西韦(n=482)。
- 主要结局为28天内至恢复时间,在改良意向治疗人群中评估。
主要发现
- 基线不需高流量氧疗者中,联合组442例有33例(7%)发生至少一次相关不良事件,单药组435例有15例(3%)。
- 基线需高流量氧疗者中,联合组35例有24例(69%)发生不良事件、21例(60%)发生严重不良事件;单药组33例有13例(39%)发生不良事件、8例(24%)发生严重不良事件。
临床怎么用
- 不推荐对住院COVID-19肺炎患者常规联合使用干扰素β-1a与瑞德西韦。
- 对基线需高流量氧疗的患者,应避免使用干扰素β-1a联合瑞德西韦。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19. METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospitalised adults (aged ≥18 years) with SARS-CoV-2 infection, as confirmed by a positive RT-PCR test, and who met one of the following criteria suggestive of lower respiratory tract infection: the presence of radiographic infiltrates on imaging, a peripheral oxygen saturation on room air of 94% or less, or requiring supplemental oxygen. Patients were excluded if they had either an alanine aminotransferase or an aspartate aminotransferase concentration more than five times the upper limit of normal; had impaired renal function; were allergic to the study product; were pregnant or breast feeding; were already on mechanical ventilation; or were anticipating discharge from the hospital or transfer to another hospital within 72 h of enrolment. Patients were randomly assigned (1:1) to receive intravenous remdesivir as a 200 mg loading dose on day 1 followed by a 100 mg maintenance dose administered daily for up to 9 days and up to four doses of either 44 μg interferon beta-1a (interferon beta-1a group plus remdesivir group) or placebo (placebo plus remdesivir group) administered subcutaneously every other day. Randomisation was stratified by study site and disease severity at enrolment. Patients, investigators, and site staff were masked to interferon beta-1a and placebo treatment; remdesivir treatment was given to all patients without masking. The primary outcome was time to recovery, defined as the first day that a patient attained a category 1, 2, or 3 score on the eight-category ordinal scale within 28 days, assessed in the modified intention-to-treat population, defined as all randomised patients who were classified according to actual clinical severity. Safety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04492475. FINDINGS: Between Aug 5, 2020, and Nov 11, 2020, 969 patients were enrolled and randomly assigned to the interferon beta-1a plus remdesivir group (n=487) or to the placebo plus remdesivir group (n=482). The mean duration of symptoms before enrolment was 8·7 days (SD 4·4) in the interferon beta-1a plus remdesivir group and 8·5 days (SD 4·3) days in the placebo plus remdesivir group. Patients in both groups had a time to recovery of 5 days (95% CI not estimable) (rate ratio of interferon beta-1a plus remdesivir group vs placebo plus remdesivir 0·99 [95% CI 0·87-1·13]; p=0·88). The Kaplan-Meier estimate of mortality at 28 days was 5% (95% CI 3-7%) in the interferon beta-1a plus remdesivir group and 3% (2-6%) in the placebo plus remdesivir group (hazard ratio 1·33 [95% CI 0·69-2·55]; p=0·39). Patients who did not require high-flow oxygen at baseline were more likely to have at least one related adverse event in the interferon beta-1a plus remdesivir group (33 [7%] of 442 patients) than in the placebo plus remdesivir group (15 [3%] of 435). In patients who required high-flow oxygen at baseline, 24 (69%) of 35 had an adverse event and 21 (60%) had a serious adverse event in the interferon beta-1a plus remdesivir group compared with 13 (39%) of 33 who had an adverse event and eight (24%) who had a serious adverse event in the placebo plus remdesivir group. INTERPRETATION: Interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia. Patients who required high-flow oxygen at baseline had worse outcomes after treatment with interferon beta-1a compared with those given placebo. FUNDING: The National Institute of Allergy and Infectious Diseases (USA).
引用
- Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 34672949. doi:10.1016/S2213-2600(21)00384-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。